Ritholtz Wealth Management lifted its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) by 11.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 405,562 shares of the biotechnology company’s stock after purchasing an additional 42,506 shares during the period. Ritholtz Wealth Management’s holdings in Aurinia Pharmaceuticals were worth $6,568,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Signaturefd LLC raised its holdings in Aurinia Pharmaceuticals by 360.0% during the 3rd quarter. Signaturefd LLC now owns 1,794 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,404 shares during the last quarter. Nykredit A S purchased a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at $35,000. Global Retirement Partners LLC purchased a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at $41,000. Quantbot Technologies LP bought a new stake in Aurinia Pharmaceuticals in the 2nd quarter worth $45,000. Finally, Allworth Financial LP bought a new stake in Aurinia Pharmaceuticals in the 2nd quarter worth $56,000. Institutional investors own 36.83% of the company’s stock.
Wall Street Analysts Forecast Growth
AUPH has been the subject of several recent analyst reports. TD Cowen upped their price objective on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. Wall Street Zen cut Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, November 4th. Royal Bank Of Canada boosted their price target on Aurinia Pharmaceuticals from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Monday, November 2nd. Finally, Bloom Burton upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.33.
Check Out Our Latest Analysis on AUPH
Aurinia Pharmaceuticals Price Performance
AUPH stock opened at $16.21 on Friday. The firm has a 50 day moving average price of $16.49 and a 200-day moving average price of $15.72. Aurinia Pharmaceuticals Inc has a 52-week low of $13.52 and a 52-week high of $19.25. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of 15.89 and a beta of 1.40. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.67 and a current ratio of 6.12.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last issued its quarterly earnings results on Friday, October 30th. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01. The firm had revenue of $83.70 million for the quarter, compared to analysts’ expectations of $83.61 million. Aurinia Pharmaceuticals had a return on equity of 22.99% and a net margin of 97.68%. Equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.97 EPS for the current fiscal year.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.
Further Reading
- Five stocks we like better than Aurinia Pharmaceuticals
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP).
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
